6090 On Other Exchanges
6090 is not on other exchanges.

human metabolome technologie (6090) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HUMAN METABOLOME TECHNOLOGIE (6090)

Related News

No related news articles were found.

human metabolome technologie (6090) Related Businessweek News

No Related Businessweek News Found

human metabolome technologie (6090) Details

Human Metabolome Technologies, Inc. engages in contract analysis, biomarker discovery, and metabolome solution sales businesses in Japan. The company provides metabolome contract analysis services; and research and development services in pharmaceutical, medical, food, and chemical fields. It is also involved in exploration and commercialization of diagnostic biomarkers in the drug development field. Human Metabolome Technologies, Inc. was founded in 2003 and is headquartered in Tsuruoka, Japan.

63 Employees
Last Reported Date: 06/28/16
Founded in 2003

human metabolome technologie (6090) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

human metabolome technologie
Human Metabolome Technologies, Inc. Presents at The 14th Annual BIO Asia International Conference, Mar-15-2017 02:15 PM

Human Metabolome Technologies, Inc. Presents at The 14th Annual BIO Asia International Conference, Mar-15-2017 02:15 PM. Venue: Grand Hyatt Tokyo, Tokyo, Japan.

Human Metabolome Technologies, Inc. Announces Consolidated Earnings Results for the First Nine Months Ended December 31, 2016; Provides Earnings Guidance for the Full Year Ending March 31, 2017

Human Metabolome Technologies, Inc. announced consolidated earnings results for the first nine months ended December 31, 2016. For the first nine months, the company announced net sales of JPY 450 million against JPY 450 million a year ago. Operating loss was JPY 168 million against JPY 167 million a year ago. Ordinary income was JPY 163 million against JPY 163 million a year ago. Loss attributable to owners of parent company was JPY 165 million or JPY 9.23 per share against JPY 162 million or JPY 30.49 per share a year ago. The company provided consolidated earnings guidance for the full year ending March 31, 2017. For the full year, the company expects to report net sales of JPY 810 million, operating loss of JPY 273 million, ordinary loss of JPY 276 million and loss attributable to owners of parent company of JPY 279 million or JPY 52.48 per share.

Human Metabolome Technologies, Inc. to Report Q3, 2017 Results on Feb 10, 2017

Human Metabolome Technologies, Inc. announced that they will report Q3, 2017 results on Feb 10, 2017


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

6090 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 6090.
View Industry Companies

Industry Analysis


Industry Average

Valuation 6090 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.3x
Price/Book 6.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HUMAN METABOLOME TECHNOLOGIE, please visit www.humanmetabolome.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.